Skip to main content
SpringerLink
Log in

Magnesium Salts in a Cancer Patient: Pathobiology and Protective Functions

  • Chapter
  • First Online:
Magnesium in Human Health and Disease

Part of the book series: Nutrition and Health ((NH))

  • 2167 Accesses

Abstract

Demographic projections show how the human population will grow in the next 50 years. The world’s population is expected to grow from 6.3 billion today to 8.9 billion in 2050. This projection assumes that family planning will offer good conditions for living at the socioeconomic level. In 2000, about 1.2 billion people lived in more developed regions: Europe, North America, Australia, New Zealand, and Japan. On the other hand, 4.9 billion people lived in the economically poor and less developed regions. Slowly growing populations (in more developed countries) have elderly dependency ratio (number of people aged above 65 to the number aged 15–64). At the opposite end, rapidly growing populations have a higher youth dependency ratio (number of people aged 0–14 to the number aged 15–64) [1].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cohen JE. Human population: the next half century. Science. 2003;302:1172–5.

    Article  PubMed  CAS  Google Scholar 

  2. Ferlay J, Bray F, Pisani P, et al. GLOBOCAN 2002: IARC Cancer Base No 5, Version 2.0. France: IARC-Press; 2004.

    Google Scholar 

  3. Beating cancer. Economist. 2004;373:9. Found online at http://www.economist.com/node/3286519

  4. Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000–02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8:784–96.

    Article  PubMed  Google Scholar 

  5. Gatta G, Zigon G, Capocaccia R, et al. Survival of European children and young adults with cancer diagnosed 1995–2002. Eur J Cancer. 2009;45:992–1005.

    Article  PubMed  Google Scholar 

  6. De Haas EC, Oosting SF, Lefrand JD, et al. The metabolic syndrome in cancer survivals. Lancet Oncol. 2010;11:193–203.

    Article  PubMed  CAS  Google Scholar 

  7. Green SP, Jones C, Stasch A. Stable magnesium(I) compounds with Mg-Mg bonds. Science. 2007;318:1754–7.

    Article  PubMed  CAS  Google Scholar 

  8. Pauling L. Magnesium. In: Pauling L, editor. General chemistry. New York: Dover Publications; 1970. p. 626–7.

    Google Scholar 

  9. Guerrera MP, Volpe SL, Mao JJ. Therapeutic uses of magnesium. Am Fam Physician. 2009;80:157–62.

    PubMed  Google Scholar 

  10. Levine BS, Coburn JW. Magnesium, the mimic/antagonist of calcium. N Engl J Med. 1984;310:1253–4.

    Article  PubMed  CAS  Google Scholar 

  11. Fawcett WJ, Haxby EJ, Male DA. Magnesium: physiology and pharmacology. Br J Anaesth. 1999;83:302–20.

    Article  PubMed  CAS  Google Scholar 

  12. Balkwill F, Manovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.

    Article  PubMed  CAS  Google Scholar 

  13. Kamiya S, Yamaguchi H, Osaki T, et al. Effect of an aluminium hydroxide-magnesium hydroxide combination drug on adhesion, IL-8 inducibility, and expression of HSP60 by Helicobacter pylori. Scand J Gastroenerol. 1999;34:663–70.

    Article  CAS  Google Scholar 

  14. Rochelson B, Dowling O, Schwartz N, et al. Magnesium sulfate suppresses inflammatory responses by human umbilical vein endothelial cells (HuVECs) through the NK-kappa pathway. J Reprod Immunol. 2007;73:101–7.

    Article  PubMed  CAS  Google Scholar 

  15. Giles SS, Czuprynski CJ. Extracellular calcium and magnesium, but not iron, are needed for optimal growth of Blastomyces dermatitidis yeast form cells. Clin Diag Lab Immunol. 2004;11:426–9.

    CAS  Google Scholar 

  16. Gunther T. Concentration, compartmentation and metabolic function of intracellular free Mg2+. Magnes Res. 2006;19:225–36.

    PubMed  CAS  Google Scholar 

  17. Hartwig A. Role of magnesium in genomic stability. Mut Res. 2001;475:113–21.

    Article  CAS  Google Scholar 

  18. Adhikari S, Toretsky JA, Yuan L, et al. Magnesium, essential for base excision repair enzymes, inhibits substrate binding of N-methylpurine-DNA glycosylase. J Biol Chem. 2006;281:29525–32.

    Article  PubMed  CAS  Google Scholar 

  19. Hibino Y, Kusashoi E, Terakawa T, et al. Enhancement of an Mg2+-dependent nuclease activity in rat liver cells exposed to cisplatin. Biochem Biophys Res Commun. 1994;202:749–56.

    Article  PubMed  CAS  Google Scholar 

  20. Mate MJ, Kleanthous C. Structure-based analysis of the metal-dependent mechanism of H-N-H endonucleases. J Biol Chem. 2004;279:34763–9.

    Article  PubMed  CAS  Google Scholar 

  21. Colegio OR, Van Itallie CM, McRea H, et al. Claudins create charge-selective channels in the paracellular pathway between epithelial cells. Am J Physiol Cell Physiol. 2002;283:C142–7.

    PubMed  CAS  Google Scholar 

  22. Konrad M, Schlingmann KP, Gudermann T. Insights into the molecular of Mg homeostasis. Am J Physiol Renal Physiol. 2004;286:F599–605.

    Article  PubMed  CAS  Google Scholar 

  23. Pearce SH, Williamson C, Kifor O, et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med. 1996;335:1115–22.

    Article  PubMed  CAS  Google Scholar 

  24. Montell C, Birnbaumer L, Flockerzi V. The TRP channels, a remarkably functional family. Cell. 2002;108:595–8.

    Article  PubMed  CAS  Google Scholar 

  25. Wissenbach U, Niemeyer BA, Flockerzi V. TRP channels as potential drug targets. Biol Cell. 2004;96:47–54.

    Article  PubMed  CAS  Google Scholar 

  26. Kiselyov K, Soyombo A, Muallem S. TRPpathies. J Physiol. 2007;578(3):641–53.

    Article  PubMed  CAS  Google Scholar 

  27. Chubanov V, Waldegger S, Mederos Y, Schnitzler M, et al. Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. PNAS. 2004;101:2894–9.

    Article  PubMed  CAS  Google Scholar 

  28. Voets T, Nilius B, Hoefs S, et al. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem. 2004;279:19–25.

    Article  PubMed  CAS  Google Scholar 

  29. Lindberg JS, Zobitz MM, Poindexter JR, et al. Magnesium bioavailability from magnesium citrate and magnesium oxide. J Am Coll Nutr. 1990;9:48–55.

    PubMed  CAS  Google Scholar 

  30. Whang R, Hampton EM, Whang DD. Magnesium homeostasis and clinical disorders of magnesium deficiency. Ann Pharmacother. 1994;28:220–6.

    PubMed  CAS  Google Scholar 

  31. Wcislo G. Molecular underpinnings of the targeted therapy for cancer. Acta Pol Pharm – Drug Res. 2008;65:633–40.

    Google Scholar 

  32. Leonard DGB, Travis LB, Addaye K, et al. p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer. Clin Cancer Res. 2002;8:973–85.

    PubMed  CAS  Google Scholar 

  33. Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med. 1999;340:351–7.

    Article  PubMed  CAS  Google Scholar 

  34. Guminski AD, Harnett PR, deFazio A. Scientists and clinicians test their metal-back to the future with platinum compounds. Lancet Oncol. 2002;3:312–8.

    Article  PubMed  Google Scholar 

  35. Pinto AL, Lippard SJ. Binding of the anti-tumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochem Biophys Acta. 1985;780:1345–57.

    Google Scholar 

  36. Huang H, Zhu L, Reid BR, et al. Solution of a cisplatin-induced DNA interstrand cross-link. Science. 1995;270:1842–5.

    Article  PubMed  CAS  Google Scholar 

  37. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol. 1999;17:409–22.

    PubMed  CAS  Google Scholar 

  38. Buckley JE, Clark VL, Meyer TJ, et al. Hypomagnesenia after cisplatin combination chemotherapy. Arch Intern Med. 1984;144:2347–8.

    Article  PubMed  CAS  Google Scholar 

  39. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. J Clin Oncol. 2005;23:5386–403.

    Article  PubMed  CAS  Google Scholar 

  40. Sawyers C. Targeted cancer therapy. Nature. 2004;432:294–7.

    Article  PubMed  CAS  Google Scholar 

  41. Ang JE, Kaye SB. Molecular targeted therapies in the treatment of ovarian cancer. Adv Gene Mol Cell Ther. 2007;1:68–79.

    Google Scholar 

  42. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009;59:111–37.

    Article  PubMed  Google Scholar 

  43. Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol. 2010;11:465–75.

    Article  PubMed  CAS  Google Scholar 

  44. Naderi ASA, Reilly RF. Hereditary etiologies of hypomagnesemia. Nat Clin Prac Nephrol. 2008;4:80–9.

    Article  CAS  Google Scholar 

  45. Wong ET, Rude RK, Singer FR. A high prevalence of hypomagnesemia in hospitalized patients. Am J Clin Pathol. 1983;79:348–52.

    PubMed  CAS  Google Scholar 

  46. Chernov B, Bamberger S, Stoiko M. Hypomagnesemia in patients in postoperative intensive care. Chest. 1989;95:391–7.

    Article  Google Scholar 

  47. Agus ZS. Hypomagnesemia. J Am Soc Nephrol. 1999;10:1616–22.

    PubMed  CAS  Google Scholar 

  48. Altura BM, Altura BT, Ising H, et al. Magnesium deficiency and hypertension: correlation between magnesium-deficient diets and microcirculatory changes in situ. Science. 1984;223:1315–7.

    Article  PubMed  CAS  Google Scholar 

  49. Hans CP, Sialy R, Bansal DD. Magnesium deficiency and diabetes mellitus. Curr Sci. 2002;83:1456–63.

    CAS  Google Scholar 

  50. Pham PC, Pham PM, Pham PA, et al. Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol. 2005;63:429–36.

    PubMed  CAS  Google Scholar 

  51. Yokota K, Kato M, Lister F, et al. Clinical efficiency of magnesium supplementation in patients with type 2 diabetes. J Am Coll Nutr. 2004;23:506S–9.

    PubMed  CAS  Google Scholar 

  52. Markman M, Rothman R, Reichman B, et al. Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer. J Cancer Res Clin Oncol. 1991;117:89–90.

    Article  Google Scholar 

  53. Mavichak V, Wong NLM, Quamme GA, et al. Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. Kidney Int. 1985;28:914–21.

    Article  PubMed  CAS  Google Scholar 

  54. Gonzalez-Vitale JC, Hayes DM, Cvitkovic E, et al. The renal pathology in clinical trials of cis-platinum (II) diamminechloride. Cancer. 1977;39:1362–71.

    Article  Google Scholar 

  55. Guinee DG, van Zee B, Houghton DC. Clinically silent progressive renal tubulointerstitial disease during cisplatin chemotherapy. Cancer. 1993;71:4050–4.

    Article  PubMed  Google Scholar 

  56. Hashizume N, Mori M. An analysis of hypermagnesemia and hypomagnesemia. Jpn J Med. 1990;29:368–72.

    Article  PubMed  CAS  Google Scholar 

  57. Ariceta G, Rodriguez-Soriano J, Vallo A, et al. Acute and chronic effects of cisplatin therapy on renal magnesium homeostasis. Med Pediatr Oncol. 1997;28:35–40.

    Article  PubMed  CAS  Google Scholar 

  58. Lajer H, Bundgaard H, Secher NH, et al. Severe intracellular magnesium and potassium depletion in patients after treatment with cisplatin. Br J Cancer. 2003;89:1633–7.

    Article  PubMed  CAS  Google Scholar 

  59. Abbasciano V, Mazzotta D, Vacchiatti G, et al. Changes in serum, erythrocyte, and urinary magnesium after a single dose of cisplatin combination chemotherapy. Magnes Res. 1991;4:123–5.

    PubMed  CAS  Google Scholar 

  60. Fine KD, Ana CAS, Porter JL, et al. Intestinal absorption of magnesium from food and supplements. J Clin Invest. 1991;88:396–402.

    Article  PubMed  CAS  Google Scholar 

  61. Coudray C, Rambeau M, Feillet-Coudray C, et al. Study of magnesium bioavailability from ten organic and inorganic Mg salts in Mg-depleted rats using a stable isotope approach. Magnes Res. 2005;18:215–23.

    PubMed  CAS  Google Scholar 

  62. Macaulay VM, Begent RH, Phillips ME, et al. Prophylaxis against hypomagnesemia induced by cis-platinum combination chemotherapy. Cancer Chemother Pharmacol. 1982;9:179–81.

    Article  PubMed  CAS  Google Scholar 

  63. Willox JC, McAllister EJ, Sangster G, et al. Effects of magnesium supplementation in testicular cancer patients receiving cisplatin: a randomised trial. Br J Cancer. 1986;54:19–23.

    Article  PubMed  CAS  Google Scholar 

  64. Netten PM, de Mulder PH, Theeuwes AG, et al. Intravenous magnesium supplementation during cisdiammine-dichlorplatinum administration prevents hypomagnesemia. Ann Oncol. 1990;1:369–72.

    PubMed  CAS  Google Scholar 

  65. Vokes EE, Mick R, Vogelzang NJ, et al. A randomised study comparing intermittent to continuous administration of magnesium aspartate hydrochloride in cisplatin-induced hypomagnesemia. Br J Cancer. 1990;62:1015–7.

    Article  PubMed  CAS  Google Scholar 

  66. Mertin M, Diaz-Rubio E, Casado A, et al. Intravenous and oral magnesium supplementation in the prophylaxis of cisplatin hypomagnesemia. Results of a controlled trial. Am J Clin Oncol. 1992;15:348–51.

    Article  Google Scholar 

  67. Evans TRJ, Harper CL, Beveridge IG, et al. A randomised study to determine whether routine intravenous ­magnesium supplements are necessary in patients receiving cisplatin chemotherapy with continuous infusion 5-fluorouracil. Eur J Cancer. 1995;31A:174–8.

    Article  PubMed  CAS  Google Scholar 

  68. Bodnar L, Wcislo G, Gasowska-Bodnar A, et al. Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer. 2008;44:2608–14.

    Article  PubMed  CAS  Google Scholar 

  69. Cunnigham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–45.

    Article  Google Scholar 

  70. Schrag D, Chung KY, Flombaum C, et al. Cetuximab therapy and symptomatic hypomagnesemia. J Natl Cancer Inst. 2005;97:1221–4.

    Article  PubMed  CAS  Google Scholar 

  71. Tejpar S, Piessevaux H, Claes K, et al. Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. Lancet Oncol. 2007;8:387–94.

    Article  PubMed  CAS  Google Scholar 

  72. Muallem S, Moe OW. When EGF is offside, magnesium is wasted. J Clin Invest. 2007;117:2086–9.

    Article  PubMed  CAS  Google Scholar 

  73. Groenestege WMT, Thebault S, van der Wijst J, et al. Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest. 2007;117:2260–7.

    Article  PubMed  CAS  Google Scholar 

  74. Thebault S, Alexander RT, Groenestege WMT, et al. EGF increases TRPM6 activity and surface expression. J Am Soc Nephrol. 2009;20:78–85.

    Article  PubMed  CAS  Google Scholar 

  75. Woudenberg-Vrenken TE, Bindels RJM, Hoenderop JGJ. The role of transient receptor potential channels in kidney disease. Nat Rev Nephrol. 2009;5:441–9.

    Article  PubMed  CAS  Google Scholar 

  76. Vincenzi B, Santani D, Galluzzo S, et al. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res. 2008;14:4219–24.

    Article  PubMed  CAS  Google Scholar 

  77. Vincenzi B, Gallauzzo S, Santini D, et al. Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. Ann Oncol. 2011;22:1141–6.

    Article  PubMed  CAS  Google Scholar 

  78. Holzner B, Kemmler G, Greil R, et al. The impact of hemoglobin levels on fatigue and quality of life In cancer patients. Ann Oncol. 2002;13:965–73.

    Article  PubMed  CAS  Google Scholar 

  79. Szenajch J, Wcislo G, Jeong J-Y, et al. The role of erythropoietin and its receptor In growth, survival and therapeutic response of human tumor cells. From clinic to bench – a critical review. Biochim Biophys Acta. 2010;1806:82–95.

    PubMed  CAS  Google Scholar 

  80. Wood PA, Hrushesky WJM. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995;95:1650–9.

    Article  PubMed  CAS  Google Scholar 

  81. Bois P. Tumour of the thymus in magnesium-deficient rats. Nature. 1964;204:1316.

    Article  PubMed  CAS  Google Scholar 

  82. Rubin H. The logic of the membrane, magnesium, mitosis (MMM) model for the regulation of Animals cell proliferation. Arch Biochem Biophys. 2007;458:16–23.

    Article  PubMed  CAS  Google Scholar 

  83. Wolf FI, Cittadini ARM, Maier JAM. Magnesium and tumors: ally or foe? Cancer Treat Rev. 2009;35:378–82.

    Article  PubMed  CAS  Google Scholar 

  84. Larsson SC, Bergkvist L, Wolk A. Magnesium intake in relation to risk of colorectal cancer in women. JAMA. 2005;293:86–9.

    Article  PubMed  CAS  Google Scholar 

  85. Folsom AR, Hong C-P. Magnesium intake and reduced risk of colon cancer in a prospective study of women. Am J Epidemiol. 2006;163:232–5.

    Article  PubMed  Google Scholar 

  86. Lin J, Cook NR, Lee I-M, et al. Total magnesium intake and colorectal cancer incidence in women. Cancer Epidemiol Biomarkers Prev. 2006;15:2006–9.

    Article  PubMed  CAS  Google Scholar 

  87. MacDonald DR. Neurotoxicity of chemotherapy agents. In: Perry MC, editor. The chemotherapy source book. Baltimore: Williams & Wilkins; 1992. p. 666–79.

    Google Scholar 

  88. Weglicki WB, Phillips TM. Pathobiology of magnesium deficiency: a cytokine/neurogenic inflammation hypothesis. Am J Physiol Regul Integr Comp Physiol. 1992;263:R734–7.

    CAS  Google Scholar 

  89. Cersosimo RJ. Cisplatin neurotoxicity. Cancer Treat Rev. 1989;16:195–211.

    Article  PubMed  CAS  Google Scholar 

  90. Thompson SW, Davis LE, Kornfeld M, et al. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer. 1984;54:1269–75.

    Article  PubMed  CAS  Google Scholar 

  91. Gregg RW, Molepo JM, Monpetit VJ, et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol. 1992;10:795–803.

    PubMed  CAS  Google Scholar 

  92. Eeles R, Tait DM, Peckham MJ. Lhermitte’s sign as a complication of cisplatin-containing chemotherapy for testicular cancer. Cancer Treat Rep. 1986;70:905–7.

    PubMed  CAS  Google Scholar 

  93. Wather PJ, Rossith E, Bullard DE. The development of Lhermitte’s sign during cisplatin chemotherapy. Cancer. 1987;60:2170–2.

    Article  Google Scholar 

  94. Wilding G, Caruso R, Lawrance TS, et al. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol. 1985;3:1683–9.

    PubMed  CAS  Google Scholar 

  95. Hartmann JT, Lipp HP. Toxicity of platinum compounds. Expert Opin Pharmacother. 2003;4:889–901.

    Article  PubMed  CAS  Google Scholar 

  96. Laurell G, Beskow C, Frankendal B, et al. Cisplatin administration to gynecologic cancer patients: long term effects on hearing. Cancer. 1996;78:1798–804.

    Article  PubMed  CAS  Google Scholar 

  97. Peters U, Preisler-Adams S, Hebeisen A, et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anti-Cancer Drugs. 2000;11:639–43.

    Article  PubMed  CAS  Google Scholar 

  98. Ashraf M, Riggs JE, Wearden S, et al. Prospective study of nerve conduction parameters and serum magnesium following cisplatin therapy. Gynecol Oncol. 1990;37:29–33.

    Article  PubMed  CAS  Google Scholar 

  99. Albers JW, Chaudrhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2011;16:CD005228.

    Google Scholar 

  100. Pace A, Giannarelli D, Galie E, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology. 2010;74:762–6.

    Article  PubMed  CAS  Google Scholar 

  101. McWhinney SR, Goldberg RM, McLeod HL, et al. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009;8:10–6.

    Article  PubMed  CAS  Google Scholar 

  102. Cvitkovic E. Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat Rev. 1998;24:265–81.

    Article  PubMed  CAS  Google Scholar 

  103. Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003;30 suppl 15:5–13.

    Article  PubMed  CAS  Google Scholar 

  104. Wilson RH, Lehky T, Thomas RR, et al. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002;20:1767–74.

    Article  PubMed  CAS  Google Scholar 

  105. Adelsberg H, Quasthoff S, Grosskreutz J, et al. The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons. Eur J Pharmacol. 2000;406:25–32.

    Article  Google Scholar 

  106. Lehky TJ, Leonard GD, Wilson RH, et al. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve. 2004;29:387–92.

    Article  PubMed  CAS  Google Scholar 

  107. Cavaletti G, Tredici G, Petruccioli MG, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer. 2001;37:2457–63.

    Article  PubMed  CAS  Google Scholar 

  108. Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002;29:11–20.

    Article  PubMed  CAS  Google Scholar 

  109. Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Therap Clin Risk Manag. 2005;1:249–58.

    CAS  Google Scholar 

  110. Amptoulach S, Tsavaris N. Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Prac. Volume 2011, Article ID 843019, 5 pages doi: 10.1155/2011/843019

  111. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study. J Clin Oncol. 2006;24:394–400.

    Article  PubMed  CAS  Google Scholar 

  112. Ishibasi K, Okada N, Miyazaki T, et al. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol. 2010;15:82–7.

    Article  CAS  Google Scholar 

  113. Gamelin L, Boisdron-Celle M, Delva R, et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res. 2004;10:4055–61.

    Article  PubMed  CAS  Google Scholar 

  114. Grothey A, Nikcevich DA, Sloan JA, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol. 2011;29:421–7.

    Article  PubMed  CAS  Google Scholar 

  115. Knijn N, Tol J, Koopman M, et al. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer. 2011;47:369–74.

    Article  PubMed  CAS  Google Scholar 

  116. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function – measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473–83.

    Article  PubMed  CAS  Google Scholar 

  117. Levy AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–47.

    Google Scholar 

  118. Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management. IRMA Study. Cancer. 2007;110:1376–84.

    Article  PubMed  CAS  Google Scholar 

  119. Superfin D, Iannucci AA, Davies AM. Commentary: oncologic drugs in patients with organ dysfunction: a summary. Oncologist. 2007;12:1070–83.

    Article  PubMed  CAS  Google Scholar 

  120. Kuhlmann MK, Burkhardt G, Jones RB, et al. Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application. Nephrol Dial Transplant. 1997;12:2478–80.

    Article  PubMed  CAS  Google Scholar 

  121. Kroning R, Lichtenstein AK, Nagami GT. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemother Pharmacol. 2000;45:43–9.

    Article  PubMed  CAS  Google Scholar 

  122. Ciarimboli G, Ludwig T, Lang D, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005;167:1477–83.

    Article  PubMed  CAS  Google Scholar 

  123. Townsend DM, Deng M, Zhang L, et al. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol. 2003;14:1–10.

    Article  PubMed  CAS  Google Scholar 

  124. Townsend DM, Hanigan MH. Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther. 2002;300:142–8.

    Article  PubMed  CAS  Google Scholar 

  125. Kawai Y, Nakao T, Kunimura N, et al. Relationship of intracellular calcium and oxygen radicals to cisplatin-related renal injury. J Pharmacol Sci. 2006;100:65–72.

    Article  PubMed  CAS  Google Scholar 

  126. Chirino YI, Hernandez-Pando R, Pedraza-Chaverri J. Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC Pharmacol. 2004;4:20.

    Article  PubMed  CAS  Google Scholar 

  127. Huang Q, Dunn IL, Jayadev S, et al. Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol Sci. 2001;63:196–207.

    Article  PubMed  CAS  Google Scholar 

  128. Arany I, Megyesi JK, Kaneto H, et al. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol. 2004;287:F543–9.

    Article  PubMed  CAS  Google Scholar 

  129. Ramesh G, Reeves WB. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest. 2002;110:835–42.

    PubMed  CAS  Google Scholar 

  130. Schilsky RL, Anderson T. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med. 1979;90:929–31.

    PubMed  CAS  Google Scholar 

  131. Skeel RT. Antineoplastic drugs and biologic response modifiers: classification, use, and toxicity of clinically useful agents. In: Skeel RT, editor. Handbook of cancer chemotherapy. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 1999. p. 89–91.

    Google Scholar 

  132. Al.-Sarraf M, Fletcher W, Oishi N, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A Southwest Oncology Group Study. Cancer Treat Rep. 1982;66:31–5.

    PubMed  CAS  Google Scholar 

  133. Pinzani V, Bressolle F, Haug IJ, et al. Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol. 1994;35:1–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Military Institute of Medicine, 128 Szaserow Str, Warsaw, 04-041, Poland

    Gabriel Wcislo M.D., Ph.D. & Lubomir Bodnar M.D., Ph.D. (Assistant Professor)

Authors
  1. Gabriel Wcislo M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lubomir Bodnar M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gabriel Wcislo M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Arizona Health Science Center, Mel and Enid Zuckerman, University of Arizona, 1295 N. Martin, Tucson, 85724-5155, Arizona, USA

    Ronald Ross Watson

  2. Dept. Nutrition & Dietetics, King's College, Stamford St. 150, London, SE1 9NH, United Kingdom

    Victor R. Preedy

  3. Division of Health Promotion Sciences, Mel and Enid Zuckerman, University of Arizona, 1295 N. Martin Avenue, Tucson, 85724, Arizona, USA

    Sherma Zibadi

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Wcislo, G., Bodnar, L. (2013). Magnesium Salts in a Cancer Patient: Pathobiology and Protective Functions. In: Watson, R., Preedy, V., Zibadi, S. (eds) Magnesium in Human Health and Disease. Nutrition and Health. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-044-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-044-1_11

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-043-4

  • Online ISBN: 978-1-62703-044-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation